Gary M Hunninghake, MD, MPH,1 Jonathan Goldin, MD, PhD,2 Howard Lazarus, MD,3 Jonathan A Kropski, MD,4 Sudhakar Pipavath, MD,5 Ivan O Rosas, MD,6 Ruchi Yadav, MD,7 Athol U Wells, MD,8 on behalf of the ILA Delphi survey group

1Pulmonary and Critical Care Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 2UCLA Department of Radiological Sciences, Santa Monica, CA, USA; 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 4Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 5University of Washington Medical Center, Seattle, WA, USA; 6Baylor College of Medicine, Houston, TX, USA; 7Cleveland Clinic, Department of Diagnostic Radiology, Cleveland, OH, USA; 8Royal Brompton Hospital, London, UK

Introduction

  • The term ILD encompasses >200 pulmonary parenchymal disorders that involve fibrosis of the lungs and other overlapping radiologic and pathologic characteristics1,2
  • Early diagnosis may facilitate early treatment that could slow ILD progression1,2
Header - Navigation Icon